Compare Gilead Sciences, Inc. (GILD) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs SoundHound AI Inc — how do they compare? Gilead Sciences, Inc. trades at $136.4 (market cap $168.47B), while SoundHound AI Inc trades at $7.39 (market cap $3.29B). The key difference: Gilead Sciences, Inc. is far larger — about 51.2× SoundHound AI Inc's market cap, and Gilead Sciences, Inc. pays a 2.41% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals.
| GILD | SOUN | |
|---|---|---|
Market Cap | $168.47B | $3.29B |
Sector | Health | Technology |
52-Week High | $155.80 | $21.40 |
52-Week Low | $110.56 | $5.70 |
Enterprise Value | $191.54B | $3.09B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
SoundHound AI (SOUN) trades at $7.40, down 0.8% on the day, with strong technical momentum indicated by bullish moving averages. The company shows impressive revenue growth of 45% in Q2 2026 and has beaten earnings expectations for three consecutive quarters. Recent news highlights the proposed LivePerson acquisition and the successful launch of the OASYS platform, which is accelerating enterprise adoption and driving improved guidance.
While growth prospects appear promising with 75% analyst buy ratings and an $8.50 consensus target, significant risks remain including persistent negative margins (-67.45% net income margin), high valuation multiples (P/S 15.31), and substantial cash burn. The stock offers growth potential but requires careful risk management given the premium valuation and path to profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
